Review

Clinical applications of pluripotent stem cells and their derivatives: current status and future perspectives

Shalmali Pendse

Anuradha Vaidya

Vaijayanti Kale

Shalmali Pendse

https://orcid.org/0000-0001-7389-3223

Symbiosis Centre for Stem Cell Research, Symbiosis International (Deemed University), Pune, 412115, India

Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Pune, 412115, India

Search for more papers by this author

Anuradha Vaidya

https://orcid.org/0000-0001-7451-7414

Symbiosis Centre for Stem Cell Research, Symbiosis International (Deemed University), Pune, 412115, India

Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Pune, 412115, India

Search for more papers by this author

Vaijayanti Kale

*Author for correspondence: Tel.: +91 20 2811 6315 6393;

E-mail Address: vaijayanti.kale@ssbs.edu.in

https://orcid.org/0000-0001-7498-7563

Symbiosis Centre for Stem Cell Research, Symbiosis International (Deemed University), Pune, 412115, India

Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Pune, 412115, India

Search for more papers by this author

Published Online:15 Jun 2022https://doi.org/10.2217/rme-2022-0045

View article

Abstract

Pluripotent stem cells (PSCs) can differentiate into specific cell types and thus hold great promise in regenerative medicine to treat certain diseases. Hence, several studies have been performed harnessing their salutary properties in regenerative medicine. Despite several challenges associated with the clinical applications of PSCs, worldwide efforts are harnessing their potential in the regeneration of damaged tissues. Several clinical trials have been performed using PSCs or their derivatives. However, the delay in publishing the data obtained in the trials has led to a lack of awareness about their outcomes, resulting in apprehension about cellular therapies. Here, the authors review the published papers containing data from recent clinical trials done with PSCs. PSC-derived extracellular vesicles hold great potential in regenerative therapy. Since published papers containing the data obtained in clinical trials on PSC-derived extracellular vesicles are not available yet, the authors have reviewed some of the pre-clinical work done with them.

Plain language summary

Embryonic stem cells (ESCs) can make all types of cells in the body. Likewise, induced pluripotent stem cells (iPSCs), which are laboratory-generated counterparts of ESCs, possess similar properties. ESCs and iPSCs have immense application in regenerative medicine, as they can be the only cure for certain diseases and conditions that are incurable with currently available treatments; however, several challenges remain. Notably, many clinical trials using these cells or their products are going on globally. However, due to the extensive time frame required to complete the clinical trials and publish the data obtained, the outcomes of these trials do not reach the general population. This delay in information flow to the public domain creates apprehension about cellular therapy. Here, the authors have reviewed recent publications documenting the results obtained in the clinical trials done with ESCs and iPSCs (together referred to as pluripotent stem cells). The vesicles (called extracellular vesicles) secreted by pluripotent stem cells also have great regenerative potential. Since published papers containing the results obtained in clinical trials done with these vesicles are not available yet, the authors have reviewed some pre-clinical work done on them.

Graphical abstract

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Barati M, Akhondi M, Mousavi NS et al. Pluripotent stem cells: cancer study, therapy, and vaccination. Stem. Cell Rev. Rep. 17(6), 1975–1992 (2021).
MedlineGoogle Scholar
2. Chan SW, Rizwan M, Yim EKF. Emerging methods for enhancing pluripotent stem cell expansion. Front. Cell Dev. Biol. 8, 70 (2020).
MedlineGoogle Scholar
3. Herberts CA, Kwa MSG, Hermsen HPH. Risk factors in the development of stem cell therapy. J. Transl. Med. 9, 29 (2011).
MedlineGoogle Scholar
4. Yamanaka S. Pluripotent stem cell-based cell therapy – promise and challenges. Cell Stem Cell 27(4), 523–531 (2020).
Medline CASGoogle Scholar
5. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res. Ther. 10(1), 68 (2019).
Medline CASGoogle Scholar
6. Eguizabal C, Aran B, Chuva de Sousa Lopes SM et al. Two decades of embryonic stem cells: a historical overview. Hum. Reprod. Open 2019(1), hoy024 (2019).
Medline CASGoogle Scholar
7. Thompson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145–1147 (1998).
MedlineGoogle Scholar
8. Mahla RS. Stem cells applications in regenerative medicine and disease therapeutics. Int. J. Cell Biol. 2016, 6940283 (2016).
MedlineGoogle Scholar
9. Desai N, Rambhia P, Gishto A. Human embryonic stem cell cultivation: historical perspective and evolution of xeno-free culture systems. Reprod. Biol. Endocrinol. 13, 9 (2015).
MedlineGoogle Scholar
10. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132(4), 661–680 (2008).
Medline CASGoogle Scholar
11. Carpenedo RL, McDevitt TC. Chapter II.1.7 – Stem cells: key concepts. In: Biomaterials Science (3rd Edition). Ratner BDHoffman ASSchoen FJLemons JE (Eds). Academic Press, MA, USA, 487–495 (2013).
Google Scholar
12. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663–676 (2006). • Paper demonstrating the creation of induced pluripotent stem cells for the first time
Medline CASGoogle Scholar
13. Omole AE, Fakoya AOJ. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ 2018(May), e4370 (2018).
Google Scholar
14. Moradi S, Mahdizadeh H, Šarić T et al. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res. Ther. 10(1), 341 (2019).
MedlineGoogle Scholar
15. Papp B, Plath K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Res. 21(3), 486–501 (2011).
Medline CASGoogle Scholar
16. Cyranoski D. The cells that sparked a revolution. Nature 555(7697), 428–430 (2018).
Medline CASGoogle Scholar
17. Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Genet. 20(7), 377–388 (2019).
Medline CASGoogle Scholar
18. Yagi T, Ito D, Okada Y et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 20(23), 4530–4539 (2011).
Medline CASGoogle Scholar
19. Chamberlain SJ. Disease modelling using human iPSCss. Hum. Mol. Genet. 25(R2), R173–R181 (2016).
Medline CASGoogle Scholar
20. Okuno H, Okano H. Modeling human congenital disorders with neural crest developmental defects using patient-derived induced pluripotent stem cells, Japanese Society of Regenerative Medicine. Regen. Ther. 18, 275–280 (2021).
Medline CASGoogle Scholar
21. Volarevic V, Markovic BS, Gazdic M et al. Ethical and safety issues of stem cell-based therapyr. Int. J. Med. Sci. 15(1), 36–45 (2018).
Medline CASGoogle Scholar
22. Lee SY, Chung SK. Integrating gene correction in the reprogramming and transdifferentiation processes: a one-step strategy to overcome stem cell-based gene therapy limitations. Stem Cell Int. 2016, 2725670 (2016).
MedlineGoogle Scholar
23. Malik N, Rao MS. A review of the methods for human iPSC derivation. Methods Mol. Biol. 997, 23–33 (2013).
Medline CASGoogle Scholar
24. Yue W, Li Y, Zhang T et al. ESC-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with Alzheimer's disease in mouse models. Stem Cell Rep. 5(5), 776–790 (2015).
Medline CASGoogle Scholar
25. Eckert A, Huang L, Gonzalez R, Kim H-S, Hamblin MH, Lee J-P. Bystander effect fuels human induced pluripotent stem cell-derived neural stem cells to quickly attenuate early stage neurological deficits after stroke. Stem Cells Transl. Med. 4(7), 841–851 (2015).
MedlineGoogle Scholar
26. Cha M-Y, Kwon Y-W, Ahn H-S et al. Protein-induced pluripotent stem cells ameliorate cognitive dysfunction and reduce Aβ deposition in a mouse model of Alzheimer's disease. Stem Cells Transl. Med. 6(1), 293–305 (2017).
Medline CASGoogle Scholar
27. Caldas HC, Lojudice FH, Dias C et al. Induced pluripotent stem cells reduce progression of experimental chronic kidney disease but develop Wilms' tumors. Stem Cells Intl 2017, 7428316 (2017).
MedlineGoogle Scholar
28. Yuan L, Liu X, Zhang L et al. A chimeric humanized mouse model by engrafting the human induced pluripotent stem cell-derived hepatocyte-like cell for the chronic hepatitis B virus infection. Front. Microbiol. 9, 908 (2018).
MedlineGoogle Scholar
29. Doi D, Magotani H, Kikuchi T et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nat. Commun. 11(1), 3369 (2020).
Medline CASGoogle Scholar
30. de Carvalho Ribeiro P, Lojudice FH, Fernandes-Charpiot IMM et al. Therapeutic potential of human induced pluripotent stem cells and renal progenitor cells in experimental chronic kidney disease. Stem Cell Res. Ther. 11(1), 530 (2020).
MedlineGoogle Scholar
31. Wu YR, Hashiguchi T, Sho J, Chiou SH, Takahashi M, Mandai M. Transplanted mouse embryonic stem cell–derived retinal ganglion cells integrate and form synapses in a retinal ganglion cell-depleted mouse model. Invest. Ophthal. Vis. Sci. 62(13), 26 (2021).
Google Scholar
32. Oswald J, Kegeles E, Minelli T, Volchkov P, Baranov P. Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas. Mol. Ther .Methods Clin. Dev. 21, 180–198 (2021).
Medline CASGoogle Scholar
33. Deuse T, Tediashvili G, Hu X et al. Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice. Proc. Natl Acad. Sci. USA 118(28), e2022091118 (2021).
Medline CASGoogle Scholar
34. Kimbrel EA, Lanza R. Pluripotent stem cells: the last 10 years. Regen. Med. 11(8), 831–847 (2016).
CASGoogle Scholar
35. Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal transplantation of embryonic stem cell–derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years. Invest. Ophthalmol. Vis. Sci. 57(5), ORSFc1–ORSFc9 (2016).
Medline CASGoogle Scholar
36. Liu Y, Xu HW, Wang L et al. Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. Cell Discov. 4, 50 (2018).
MedlineGoogle Scholar
37. Smith EN, D'Antonio-Chronowska A, Greenwald WW et al. Human iPSC-derived retinal pigment epithelium: a model system for prioritizing and functionally characterizing causal variants at AMD risk loci. Stem Cell Rep. 12(6), 1342–1353 (2019).
Medline CASGoogle Scholar
38. Geng Z, Walsh PJ, Truong V et al. Generation of retinal pigmented epithelium from iPSCs derived from the conjunctiva of donors with and without age related macular degeneration. PLoS One 12(3), e0173575 (2017).
MedlineGoogle Scholar
39. Ye K, Takemoto Y, Ito A et al. Reproducible production and image-based quality evaluation of retinal pigment epithelium sheets from human induced pluripotent stem cells. Sci. Rep. 10(1), 14387 (2020).
Medline CASGoogle Scholar
40. Gong J, Cai H, Noggle S et al. Stem cell-derived retinal pigment epithelium from patients with age-related macular degeneration exhibit reduced metabolism and matrix interactions. Stem Cell Transl. Med. 9(3), 364–376 (2020).
Medline CASGoogle Scholar
41. Hazim RA, Karumbayaram S, Jiang M et al. Differentiation of RPE cells from integration-free iPS cells and their cell biological characterization. Stem Cell Res. Ther. 8(1), 217 (2017).
MedlineGoogle Scholar
42. Zhu D, Xie M, Gademann F et al. Protective effects of human iPS-derived retinal pigmented epithelial cells on retinal degenerative disease. Stem Cell Res. Ther. 11(1), 98 (2020).
Medline CASGoogle Scholar
43. Qiu TG. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration. NPJ Regen. Med. 4, 19 (2019).
MedlineGoogle Scholar
44. Wang Y, Tang Z, Gu P. Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials. Cell Death Dis. 11(9), 793 (2020).
MedlineGoogle Scholar
45. Li SY, Liu Y, Wang L et al. A phase I clinical trial of human embryonic stem cell-derived retinal pigment epithelial cells for early-stage Stargardt macular degeneration: 5-years' follow-up. Cell Prolif. 54(9), e13100 (2021).
MedlineGoogle Scholar
46. Mandai M, Watanabe A, Kurimoto Y et al. Autologous induced stem-cell–derived retinal cells for macular degeneration. N. Engl. J. Med. 376(11), 1038–1046 (2017).
Medline CASGoogle Scholar
47. Takagi S, Mandai M, Gocho K et al. Evaluation of transplanted autologous induced pluripotent stem cell-derived retinal pigment epithelium in exudative age-related macular degeneration. Ophthalmol. Retina 3(10), 850–859 (2019).
MedlineGoogle Scholar
48. Chen S, Du K, Zou C. Current progress in stem cell therapy for Type 1 diabetes mellitus. Stem Cell Res. Ther. 11(1), 275 (2020).
MedlineGoogle Scholar
49. Corrêa-Giannella ML, Raposo do Amaral AS. Pancreatic islet transplantation. Diabetol. Metab. Syndr. 1(1), 9 (2009).
MedlineGoogle Scholar
50. Cayabyab F, Nih LR, Yoshihara E. Advances in pancreatic islet transplantation sites for the treatment of diabetes. Front. Endocrinol. 12, 732431 (2021).
MedlineGoogle Scholar
51. Bellin MD, Dunn TB. Transplant strategies for Type 1 diabetes: whole pancreas, islet and porcine beta cell therapies. Diabetologica 63(10), 2049–2056 (2020).
MedlineGoogle Scholar
52. Kondo Y, Toyoda T, Inagaki N, Osafune K. iPSC technology-based regenerative therapy for diabetes. J. Diabetes Investig. 9(2), 234–243 (2018).
MedlineGoogle Scholar
53. Ramzy A, Thompson DM, Ward-Hartstonge KA et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with Type 1 diabetes. Cell Stem Cell 28(12), 2047–2061.e5 (2021).• Breakthrough clinical study demonstrating the use of pluripotent stem cells in cardiovascular disease
Medline CASGoogle Scholar
54. Shapiro AMJ, Thompson D, Donner TW et al. Insulin expression and C-peptide in Type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Rep. Med. 2(12), 100466 (2021).• Associating clinical study demonstrating the use of pluripotent stem cells in cardiovascular disease.
MedlineGoogle Scholar
55. Silver SE, Barrs RW, Mei Y. Transplantation of human pluripotent stem cell-derived cardiomyocytes for cardiac regenerative therapy. Front. Cardiovasc. Med. 8, 707890 (2021).
Medline CASGoogle Scholar
56. Turner D, Rieger AC, Balkan W, Hare JM. Clinical-based cell therapies for heart disease – current and future state. Rambam Maimonides Med. J. 11(2), e0015 (2020).
Google Scholar
57. Menasché P, Vanneaux V, Hagège A et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 71(4), 429–438 (2018).
MedlineGoogle Scholar
58. Sivandzade F, Cucullo L. Regenerative stem cell therapy for neurodegenerative diseases: an overview. Int. J. Mol. Sci. 22(4), 2153 (2021).
Medline CASGoogle Scholar
59. Sugai K, Sumida M, Shofuda T et al. First-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: study protocol. Regen. Ther. 18, 321–333 (2021).
Medline CASGoogle Scholar
60. Takahashi J. iPS cell-based therapy for Parkinson's disease: a Kyoto trial. Regen. Ther. 13, 18–22 (2020). • An important study underscoring the efficacy of induced pluripotent stem cells in neurodegenerative diseases at a pre-clinical level. The clinical study was initiated on the basis of this study.
MedlineGoogle Scholar
61. Schweitzer JS, Song B, Herrington TM et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. N. Engl. J. Med. 382(20), 1926–1932 (2020).
Medline CASGoogle Scholar
62. Armijo E, Edwards G, Flores A et al. Induced pluripotent stem cell-derived neural precursors improve memory, synaptic and pathological abnormalities in a mouse model of Alzheimer's disease. Cells 10(7), 1802 (2021).
Medline CASGoogle Scholar
63. Bhartiya D. Clinical translation of stem cells for regenerative medicine: a comprehensive analysis. Circ. Res.. 124(6), 840–842 (2019).
Medline CASGoogle Scholar
64. Solomon S, Pitossi F, Rao MS. Banking on iPSC – is it doable and is it worthwhile. Stem Cell Rev. Rep. 11(1), 1–10 (2015).
Medline CASGoogle Scholar
65. Jeske R, Bejoy J, Marzano M, Li Y. Human pluripotent stem cell-derived extracellular vesicles: characteristics and applications, mary ann liebert inc. Tissue Eng. Part B Rev. 26(2), 129–144 (2020).
MedlineGoogle Scholar
66. Lener T, Gimona M, Aigner L et al. Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. J. Extracell. Vesicles 4, 30087 (2015).
MedlineGoogle Scholar
67. He F, Li L, Fan R, Wang X, Chen X, Xu Y. Extracellular vesicles: an emerging regenerative treatment for oral disease. Front. Cell Dev. Biol. 9, 669011 (2021).
MedlineGoogle Scholar
68. Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell–cell messengers in cardiovascular diseases. Circ. Res. 114(2), 345–353 (2014).
Medline CASGoogle Scholar
69. Todorova D, Simoncini S, Lacroix R, Sabatier F, Dignat-George F. Extracellular vesicles in angiogenesis. Circ. Res. 120(10), 1658–1673 (2017).
Medline CASGoogle Scholar
70. Collino F, Lopes JA, Tapparo M et al. Extracellular vesicles derived from induced pluripotent stem cells promote renoprotection in acute kidney injury model. Cells 9(2), 453 (2020).
CASGoogle Scholar
71. Ratajczak J, Miekus K, Kucia M et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20(5), 847–856 (2006).
Medline CASGoogle Scholar
72. Yuan Y, Du W, Liu J et al. Stem cell-derived exosome in cardiovascular diseases: macro roles of micro particles. Front. Pharmocol. 9, 547 (2018).
MedlineGoogle Scholar
73. Wu Q, Wang J, Tan WLW et al. Extracellular vesicles from human embryonic stem cell-derived cardiovascular progenitor cells promote cardiac infarct healing through reducing cardiomyocyte death and promoting angiogenesis. Cell Death Dis. 11(5), 354 (2020).
MedlineGoogle Scholar
74. Khan M, Nickoloff E, Abramova T et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ. Res. 117(1), 52–64 (2015).
Medline CASGoogle Scholar
75. Pang Y, Ma M, Wang D et al. Embryonic stem cell-derived exosomes attenuatetransverse aortic constriction induced heart failure by increasing angiogenesis. Front. Cardiovasc. Med. 8, 638771 (2021).
Medline CASGoogle Scholar
76. el Harane N, Kervadec A, Bellamy V et al. Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors. Eur. Heart J. 39(20), 1835–1847 (2018).
Medline CASGoogle Scholar
77. Correa BL, el Harane N, Desgres M et al. Extracellular vesicles fail to trigger the generation of new cardiomyocytes in chronically infarcted hearts. Theranostics 11(20), 10114–10124 (2021).
Medline CASGoogle Scholar
78. Santoso MR, Ikeda G, Tada Y et al. Exosomes from induced pluripotent stem cell–derived cardiomyocytes promote autophagy for myocardial repair. J. Am. Heart Assoc. 9(6), e014345 (2020).
Medline CASGoogle Scholar
79. Liu M, Qiu Y, Xue Z et al. Small extracellular vesicles derived from embryonic stem cells restore ovarian function of premature ovarian failure through PI3K/AKT signaling pathway. Stem Cell Res. Ther. 11(1), 3 (2020).
Medline CASGoogle Scholar
80. Yu L, Liu S, Wang C et al. Embryonic stem cell-derived extracellular vesicles promote the recovery of kidney injury. Stem Cell Res. Ther. 12(1), 379 (2021).
Medline CASGoogle Scholar
81. Saint-Pol J, Gosselet F, Duban-Deweer S, Pottiez G, Karamanos Y. Targeting and crossing the blood–brain barrier with extracellular vesicles. Cells 9(4), 851 (2020).
CASGoogle Scholar
82. Zhu Q, Ling X, Yang Y et al. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy. Adv. Sci. 6(6), 1801899 (2019).
Google Scholar
83. Fan C, Zhang E, Joshi J, Yang J, Zhang J, Zhu W. Utilization of human induced pluripotent stem cells for cardiac repair. Front. Cell Dev. Biol. 8, 36 (2020).
MedlineGoogle Scholar
84. Adamiak M, Cheng G, Bobis-Wozowicz S et al. Induced pluripotent stem cell (iPSC)-derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs. Circ. Res. 122(2), 296–309 (2018).
Medline CASGoogle Scholar
85. Zhu Y, Wang Y, Zhao B et al. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res. Ther. 8(1), 64 (2017).
MedlineGoogle Scholar
86. Han Z, Liu S, Pei Y et al. Highly efficient magnetic labelling allows MRI tracking of the homing of stem cell-derived extracellular vesicles following systemic delivery. J. Extracell. Vesicles 10(3), e12054 (2021).
Medline CASGoogle Scholar
87. Kulkarni R, Bajaj M, Ghode S, Jalnapurkar S, Limaye L, Kale VP. Intercellular transfer of microvesicles from young mesenchymal stromal cells rejuvenates aged murine hematopoietic stem cells. Stem Cells 36(3), 420–433 (2018).
Medline CASGoogle Scholar
88. Jalnapurkar S, Moirangthem RD, Singh S, Limaye L, Kale V. Microvesicles secreted by nitric oxide-primed mesenchymal stromal cells boost the engraftment potential of hematopoietic stem cells. Stem Cells 37(1), 128–138 (2019).
Medline CASGoogle Scholar
89. Gorecka J, Kostiuk V, Fereydooni A et al. The potential and limitations of induced pluripotent stem cells to achieve wound healing. Stem Cell Res. Ther. 10(1), 1–10 (2019).
Medline CASGoogle Scholar
90. Baldari S, Di Rocco G, Piccoli M, Pozzobon M, Muraca M, Toietta G. Challenges and strategies for improving the regenerative effects of mesenchymal stromal cell-based therapies. Int. J. Mol. Sci. 18(10), 2087 (2017).
Google Scholar
91. Simeon M, Dangwal S, Sachinidis A, Doss MX. Application of the pluripotent stem cells and genomics in cardiovascular research – what we have learnt and not learnt until now. Cells 10(11), 3112 (2021).
Medline CASGoogle Scholar
92. O'Shea O, Steeg R, Chapman C, Mackintosh P, Stacey GN. Development and implementation of large-scale quality control for the European bank for induced pluripotent stem cells. Stem Cell Res. 45, 101773 (2020).
MedlineGoogle Scholar
93. Steeg R, Neubauer JC, Müller SC, Ebneth A, Zimmermann H. The EBiSC iPSC bank for disease studies. Stem Cell Res. 49, 102034 (2020).
Medline CASGoogle Scholar
94. Huang CY, Liu CL, Ting CY et al. Human iPSC banking: barriers and opportunities. J. Biomed. Sci. 26(1), 87 (2019).
MedlineGoogle Scholar
95. Kawase E, Takada K, Suemori H. Kyoto hESC cell resource for regenerative medicine. Stem Cell Res. 49, 102020 (2020).
MedlineGoogle Scholar
96. Umekage M, Sato Y, Takasu N. Overview: an iPS cell stock at CiRA. Inflamm. Regen. 39, 17 (2019).
MedlineGoogle Scholar
97. Flahou C, Morishima T, Takizawa H, Sugimoto N. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Front. Immunol. 12, 662360 (2021).
Medline CASGoogle Scholar
98. Sackett SD, Brown ME, Tremmel DM, Ellis T, Burlingham WJ, Odorico JS. Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation. Transpl. Revs (Orlando, Fla.) 30(2), 61–70 (2016).
Medline CASGoogle Scholar
99. Karagiannis P, Nakauchi A, Yamanaka S. Bringing induced pluripotent stem cell technology to the bedside. JMA J. 1(1), 6–14 (2018).
MedlineGoogle Scholar
100. Koga K, Wang B, Kaneko S. Current status and future perspectives of HLA-edited induced pluripotent stem cells. Inflamm. Regen. 40, 23 (2020).
Medline CASGoogle Scholar
101. Jang Y, Choi J, Park N et al. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Exp. Mol. Med. 51(1), 1–11 (2019).
Google Scholar
102. Xu H, Wang B, Ono M et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24(4), 566–578.e7 (2019).
Medline CASGoogle Scholar
103. Han X, Wang M, Duan S et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc. Natl Acad. Sci. USA 116(21), 10441–10446 (2019).
Medline CASGoogle Scholar

Vol. 17, No. 9

Supplemental Materials

Metrics

Downloaded 409 times

History

Received 16 March 2022

Accepted 17 May 2022

Published online 15 June 2022

Published in print September 2022

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/rme-2022-0045

Author contributions

S Pendse: writing – original draft preparation; A Vaidya: visualization, writing – reviewing and editing; V Kale: conceptualization, visualization, writing – reviewing and editing, supervision.

Acknowledgments

The authors would like to thank the Symbiosis Centre for Research & Innovation (SCRI), Symbiosis International (Deemed University), for providing Senior Research Fellowship (JRF) to S Pendse and infrastructural support.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download